RESEARCH TRIANGLE PARK, N.C. – April 10, 2008 – Quintiles Transnational Corp. today announced that an independently conducted study of clinical investigator sites across Europe placed Quintiles first in overall satisfaction. Quintiles also rated first in several other indicators of a clinical investigator’s commitment to work with the world’s leading pharmaceutical services provider.
Eighty-four percent of sites indicated that they were satisfied or extremely satisfied with their relationship with Quintiles.
The study, blinded and conducted by a third party, asked more than 300 European clinical investigators in 18 countries to rate their relationships and experience with Clinical Research Organizations (CROs). Investigators recruit patients and collect data for CROs and their pharmaceutical and biotechnology sponsors in studies that test drugs for safety and efficacy. Quintiles and eight other CROs were rated on 15 attributes by the investigator sites, including overall satisfaction, relationship building and allocation of resources for projects, including staff time.
“It is especially pleasing to see these results from all of our efforts to build strong relationships with investigators,” said Lindy Jones, Vice President, Clinical Operations, Western Europe and Africa. “Because of our hard work, it is clear the sites are willing to devote more of their resources to projects they conduct with Quintiles than other CROs.”
Clinical sites were asked to assign a percentage of resources -- such as time spent on patient recruitment – that they had used on clinical studies with each CRO. Quintiles was allocated 38% of resources by the sites, with the nearest competitor being assigned only 13%, according to the survey. As for expected allocation of resources in the future, sites plan to continue giving additional resources to Quintiles projects at about a 3:1 ratio over other CROs.
“Allocation of resource is an important measure because it tells us where sites are more willing to put their limited time and effort,” said Jones. “These results show that sites feel they get more return on their investment by working with Quintiles.”
The relationship measurement was based on the question, “Which provider works hardest to develop a relationship with you/your site?” Quintiles was named by 49% of respondents. The closest competitor was named by only 10%.
Janos Filakovsky, Vice President and Managing Director, Eastern Region and Middle East, said, “Our continuing efforts to build strong relationships ultimately lead to more efficient use of time and resources, and that makes our customers happy. The end goal is more accurate feasibility, faster recruitment and safer patient management in clinical trials.”
A third-party research company interviewed 308 investigators across Europe from January to February 2008. Investigators rated only those CROs with whom they had worked in the last 18 months. Respondents had an average of 13 years of experience in conducting clinical research, and sites had conducted an average of 11 studies over the last 18 months. For source data, please refer to www.quintiles.com/results.
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With more than 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company’s Web site at www.quintiles.com.